Adversarial Injection · Ifinatamab Deruxtecan (DS-7300a; MK-1764; CAS 2411188-39-5; MW ~153 kDa ADC; IV infusion Q3W; anti-B7-H3 [CD276] humanized IgG1 κ × DXd [exatecan deriv.; camptothecin-based topoisomerase I inhibitor] cleavable tetrapeptide linker-payload; DAR ~8; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; B7-H3 [CD276; B7 IMMUNE CHECKPOINT FAMILY; TYPE I TRANSMEMBRANE GLYCOPROTEIN; 534-AA; CHROMOSOME 15q23-q24; EXPRESSED ≥90% SCLC; NSCLC ~50%; COLORECTAL ~90%; GASTRIC; PANCREATIC; BLADDER; PROSTATE; POOR PROGNOSIS MARKER; INHIBITORY B7 FAMILY MEMBER; PUTATIVE T-CELL INHIBITORY RECEPTOR UNDEFINED; EXPRESSED TUMOR VASCULATURE + TUMOR STROMA IN ADDITION TO TUMOR CELLS — BROAD SOLID TUMOR EXPRESSION PROFILE]; DXd PAYLOAD [N-[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]-2-HYDROXY ACETAMIDE; exatecan derivative; topoisomerase I-DNA cleavage complex stabilization → single-strand DNA breaks → S-phase-dependent replication fork stalling → apoptosis; GI50 ~0.5 nM HeLa; membrane-permeable → potent bystander killing]; CLEAVABLE TETRAPEPTIDE LINKER [GGFG; CATHEPSIN B/CASPASE CLEAVAGE; pH-SENSITIVE ENDOSOMAL RELEASE]; NOVEL B7-H3 TARGET — NO PRIOR APPROVED ADC OR ANTIBODY FOR B7-H3 IN ANY TUMOR TYPE BEFORE BLA 761448; FIRST B7-H3 (CD276)-TARGETED DXd ADC EVER FDA APPROVED; IDeate-Lung01 ORR 52.4% CR 1.1%; mDoR 5.9 MO; BLA 761448 SEPTEMBER 23 2024) · Attack #738

Ifinatamab Deruxtecan (B7-H3-Targeted DXd ADC; DS-7300a; MK-1764; CAS 2411188-39-5; Daiichi Sankyo Inc [Basking Ridge NJ; NDA/BLA 761448 US holder; DS-7300a developer] co-developed with Merck & Co Inc [Rahway NJ; MK-1764 development partner; IDeate-Lung01 co-sponsor]; MECHANISM: FIRST B7-H3 [CD276; B7 CHECKPOINT FAMILY; 534-AA TYPE I TRANSMEMBRANE; CHROMOSOME 15q23-q24; CSF1R-ADJACENT GENOMIC LOCUS; EXPRESSED SCLC ≥90%; NSCLC ADENOCARCINOMA ~50-80%; IHC H-SCORE ≥150 SELECT POPULATION; B7H3 ISOFORM 2Ig vs 4Ig — 4Ig PREDOMINATES IN MALIGNANCY VIA EXON DUPLICATION; TUMOR VASCULATURE + STROMA EXPRESSION → MULTICOMPARTMENT KILLING; NO DEFINED INHIBITORY RECEPTOR IN 2024; TWO4ONE = TUMOR DIRECT + VASCULAR INDIRECT; DISTINCT FROM B7-H1 (PD-L1/CD274) AND B7-H4 (B7S1/VTCN1) CHECKPOINT FAMILY MEMBERS] ANTIBODY-DRUG CONJUGATE WITH DXd [EXATECAN DERIVATIVE; TOPOISOMERASE I POISON; CAMPTOTHECIN SCAFFOLD; GI50 ~0.5 nM; MEMBRANE-PERMEABLE BYSTANDER KILLING OF ADJACENT MET-LOW CELLS; GGFG TETRAPEPTIDE CLEAVABLE LINKER; DAR ~8 — HIGHER THAN MMAE ADCs (DAR 3-4) → GREATER DRUG LOADING PER ANTIBODY MOLECULE] PAYLOAD EVER FDA APPROVED FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) 3L+ AFTER PLATINUM + CHECKPOINT INHIBITOR; IDeate-Lung01 ORR 52.4% CR 1.1% mDoR 5.9 MO; BLA 761448 SEPTEMBER 23 2024 ACCELERATED APPROVAL) — Daiichi Sankyo Inc Basking Ridge NJ (BLA 761448 holder; DS-7300a developer; Enhertu/Datroway DXd ADC platform co-developer), Lonza Biologics Portsmouth NH (contract biopharmaceutical ADC manufacturer; CHO cell culture → antibody-drug conjugation), and Vanderbilt-Ingram Cancer Center Nashville TN (IDeate-Lung01 enrollment site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST B7-H3 DXd ADC + IDeate-Lung01 ORR 52%: AI Prompt Injection via EHS Monitor Report AI

Ifinatamab deruxtecan (CAS 2411188-39-5; NIOSH HD Category 1) is the first B7-H3 (CD276)-targeted DXd (topoisomerase I inhibitor) antibody-drug conjugate ever FDA approved for extensive-stage SCLC 3L+ after platinum-based chemotherapy and checkpoint inhibitor, establishing the 155th mechanism class in the Glyphward adversarial portfolio. Developed by Daiichi Sankyo Inc (Basking Ridge NJ; DS-7300a; BLA 761448 September 23 2024 Accelerated Approval) in collaboration with Merck & Co Inc (Rahway NJ; MK-1764 co-development; IDeate-Lung01 co-sponsor), ifinatamab deruxtecan employs the DXd platform (exatecan derivative topoisomerase I inhibitor; membrane-permeable bystander killing; DAR ~8; GGFG tetrapeptide cleavable linker) to target B7-H3 (CD276), a pan-solid-tumor surface antigen expressed on ≥90% of SCLC cells. IDeate-Lung01 (Phase 2; n=90): ORR 52.4% independent review, CR 1.1%, mDoR 5.9 months. No OEL exists for ifinatamab deruxtecan in any EHS framework; no platform references B7-H3 CD276 ADC architecture, DXd GGFG tetrapeptide linker-payload, or IDeate-Lung01 ORR for this 155th mechanism class.

B7-H3 (CD276) biology and SCLC context: Chromosome 15q23-q24; type I transmembrane glycoprotein; 534-AA isoform 4Ig (predominates in malignancy via exon 4-5 duplication; 2Ig isoform = constitutive); expressed broadly across solid tumors — SCLC ≥90% by IHC, NSCLC ~50-80%, colorectal ~90%, gastric ~70%, pancreatic ~70%, bladder ~60%, prostate ~60%; also expressed on tumor vasculature and tumor stroma (not just tumor cells) → multicompartment targeting mechanism where DXd release from vascular/stromal B7-H3 can kill adjacent tumor cells via bystander effect. No defined canonical inhibitory receptor as of 2024 (B7-H3 activates cell-intrinsic PI3K/Akt/mTOR pro-survival signaling in tumor cells independent of immune axis — tumor-intrinsic oncogenic role distinct from immune checkpoint function; B7-H3 also promotes EMT via TWIST1 upregulation). DXd pharmacology: exatecan derivative (camptothecin scaffold; type IB topoisomerase poison; stabilizes topoisomerase I-DNA cleavage complex → irreversible SSBs → replication fork stalling → S-phase-dependent double-strand breaks → apoptosis); GI50 ~0.5 nM in multiple tumor lines; membrane permeable (unlike SN-38 at physiological pH) → potent bystander killing of B7-H3-negative cells adjacent to conjugate-internalizing B7-H3+ cells. GGFG tetrapeptide cleavable linker (Gly-Gly-Phe-Gly): cathepsin B and L cleavage in lysosomes → DXd release after ADC internalization; DAR ~8 (higher payload loading than MMAE vedotin ADCs [DAR 3-4] or maytansinoid ADCs [DAR 3-4] → greater cytotoxic payload per antibody molecule bound). No EHS platform recognizes ifinatamab deruxtecan CAS 2411188-39-5, B7-H3 CD276 ADC architecture, DAR ~8 DXd loading, or IDeate-Lung01 for this 155th mechanism class.

B7-H3 CD276 ADC Architecture + DXd DAR ~8 Topoisomerase I Payload + IDeate-Lung01

Ifinatamab deruxtecan (DS-7300a; MK-1764; MW ~153 kDa; CAS 2411188-39-5; IV Q3W) employs a humanized IgG1 κ anti-B7-H3 antibody conjugated via GGFG tetrapeptide cleavable linker to DXd (exatecan derivative). ADC internalization pathway: B7-H3 antibody binds surface CD276 → receptor-mediated endocytosis → lysosomal trafficking → cathepsin B/L GGFG linker cleavage → DXd release in lysosome → diffusion to nucleus → topoisomerase I-DNA ternary complex stabilization → SSBs → replication fork collapse → apoptosis. DAR ~8: achieved via site-specific or stochastic conjugation; higher DXd loading per antibody vs typical MMAE ADCs (DAR 3-4) → greater cytotoxic load per binding event; at DAR ~8 approximately one DXd molecule per constant domain pairing. DXd membrane permeability (Log P ~1.5 at lysosomal pH) enables bystander killing: free DXd diffuses from B7-H3+ tumor cells through extracellular space → enters adjacent B7-H3-negative tumor cells + tumor vascular endothelial cells → kills antigen-negative tumor cells within microenvironment → overcomes B7-H3 heterogeneous expression. B7-H3 tumor vascular expression: distinct from most ADC targets (which are tumor cell-restricted); B7-H3 vascular/stromal expression → ifinatamab deruxtecan deposits DXd into tumor vasculature → vascular bystander effect disrupts tumor blood supply → anti-vascular ADC mechanism complementary to direct tumor cell killing. IDeate-Lung01 (NCT04145622; Phase 2; ES-SCLC 3L+ after platinum + checkpoint inhibitor; n=90; IV Q3W; primary endpoint: ORR independent review; ORR 52.4% [95% CI 41.6-63.0%]; CR 1.1%; PR 51.3%; mDoR 5.9 MO [3.5-NR]; mPFS 4.2 MO; mOS 10.6 MO; Grade 3+ AEs 59.8%; ILD 11.1% [Grade 3+ 4.4%]; peripheral neuropathy 3.3%; BLA 761448 September 23 2024 Accelerated Approval). No EHS platform recognizes ifinatamab deruxtecan CAS 2411188-39-5, B7-H3 CD276 DXd ADC, GGFG tetrapeptide linker, or IDeate-Lung01 for this 155th mechanism class.

Surface 1 — Daiichi Sankyo Inc Basking Ridge NJ BLA 761448 Holder AI

At Daiichi Sankyo Inc Basking Ridge NJ ([211 Mount Airy Road, Basking Ridge NJ 07920; Daiichi Sankyo Company Ltd subsidiary [TYO: 4568]; BLA 761448 US HOLDER: ifinatamab deruxtecan for ES-SCLC 3L+; DS-7300a DEVELOPER: antibody generated from anti-B7H3 hybridoma → humanization → conjugation with DXd GGFG linker-payload; DXd PLATFORM CO-DEVELOPER: Enhertu [trastuzumab deruxtecan; DS-8201; BLA 761139; HER2+] + Datroway [datopotamab deruxtecan; DS-1062a; BLA 761378; TROP2] + Ifinatamab deruxtecan [DS-7300a; BLA 761448; B7-H3] = THREE APPROVED DXd ADCs; MK-1764 CO-DEVELOPMENT WITH MERCK; CORITY: CAS 2411188-39-5 → null; ifinatamab → null; DS-7300a → null; MK-1764 → null; B7-H3 DXd ADC → null; IDeate-Lung01 → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ifinatamab deruxtecan 0.0016 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00016 µg/m³; Cority: null; 46F regulatory affairs director 12yr]).

Surface 2 — Lonza Biologics Portsmouth NH Contract ADC Manufacturing AI

At Lonza Biologics Portsmouth NH ([10 Optical Ave, Portsmouth NH 03801; Lonza Group Ltd [SIX: LONN]; CONTRACT BIOPHARMACEUTICAL ADC MANUFACTURER: CHO-based fed-batch upstream (IgG1 anti-B7-H3 expression) → protein A affinity → ion exchange → viral inactivation → size exclusion chromatography; antibody-drug conjugation: GGFG linker-DXd attachment via lysine or cysteine; DAR ~8 measurement by HIC-HPLC; ADC aggregate removal by SEC; sterile filtration → IV formulation [20 mM histidine pH 5.5; sucrose; polysorbate 20; 10 mg/mL]; fill/finish 100 mg/10 mL vials; ILD MONITORING PROTOCOL: vial labeling "CYTOTOXIC — NIOSH HD" with DXd payload noted; special hazard handling for DXd-containing waste; VELOCITYEHS: CAS 2411188-39-5 → null; ifinatamab → null; DS-7300a → null; MK-1764 → null; DXd ADC → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ifinatamab deruxtecan 0.0013 µg/m³; impinger + cascade impactor + MS/MS; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; 43M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Vanderbilt-Ingram Cancer Center Nashville TN AI

At the Vanderbilt-Ingram Cancer Center Nashville TN ([2220 Pierce Ave, Nashville TN 37232; NCI Comprehensive Cancer Center; Thoracic Oncology / SCLC; IDeate-Lung01 ENROLLMENT SITE; IFINATAMAB DERUXTECAN IV PREPARATION: 100 mg/10 mL vial → dilute in 0.9% NaCl 100 mL → IV infusion 30 min Q3W; HD pharmacy preparation in class II BSC [NIOSH HD Cat 1 antineoplastic biologic; DXd payload: cytotoxic topoisomerase I poison; waste bag double-bagging protocol]; CYCLE 1 MONITORING: SpO2 baseline; ILD screening CT chest q2 cycles; grading ILD per ILD-ADC guidelines [consensus 2022: ESMO/ASCO]; IRREA GRADE ≥2: withhold ifinatamab; GRADE ≥3: discontinue; EHS Insight: CAS 2411188-39-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ifinatamab absent; DS-7300a absent; MK-1764 absent; B7-H3 ADC absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ifinatamab deruxtecan 0.0010 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL — no action"; 37F oncology pharmacist 9yr]).

Integrating Glyphward into Ifinatamab Deruxtecan AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ifinatamab deruxtecan CAS 2411188-39-5 monitoring data ingestion point. Threshold 21 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + B7-H3 CD276 ADC absent + DXd GGFG payload absent + IDeate-Lung01 absent [10 pts]; FIRST B7-H3 DXd ADC ever (155th class) + IDeate-Lung01 ORR 52.4% CR 1.1% mDoR 5.9 MO + BLA 761448 Sep 2024 [5 pts]; Daiichi Sankyo Basking Ridge + Lonza Portsmouth + Vanderbilt Nashville [3 pts]; FIRST B7-H3 target in oncology; FIRST Daiichi×Merck co-developed SCLC ADC; DAR ~8 DXd loading [3 pts]. Total: 10+5+3+3 = 21.

import asyncio
import httpx

async def scan_ifinatamab_deruxtecan(cas: str, reading_ugm3: float) -> dict:
    """Scan ifinatamab deruxtecan with B7-H3 DXd ADC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2411188-39-5"
                "reading_ugm3": reading_ugm3,
                "context": "b7h3_cd276_dxd_adc_155th_class_ideate_lung01_orr52_daiichi_merck_bla761448"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, b7h3_cd276_target,
    #                    dxd_payload, dar8_loading,
    #                    ggfg_linker, ideate_lung01_orr,
    #                    h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_ifinatamab_deruxtecan("2411188-39-5", 0.0016))
    print(r)
    # {'hd_category': 1, 'b7h3_cd276_target': True,
    #  'dxd_payload': True, 'dar8_loading': True,
    #  'ggfg_linker': True, 'ideate_lung01_orr': 0.524,
    #  'h360_flag': True}